Massive Bio Supports Cancer Associations
Massive Bio announced the launch of “Donation for Life,” a new awareness campaign created to support cancer associations and foundations in the United States and Europe.
…
Read More
Eyenovia Aims to Revolutionize Ophthalmology Devices With Microdose Array Print (MAP) Technology
The Microdose Array Print (MAP) Technology has shown potential in clinical trials, providing the possibility of more accurate ocular drug delivery than traditional eye droppers
…
Read More
Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform
Gb Sciences’ innovative approach harnesses the power of plant-based treatments as simplified mixtures that target dangerous hyperinflammatory responses to viral infections.
LAS VEGAS – December 22, 2022 – (Newswire.com)
Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, is developing cannabis-inspired anti-inflammatory therapeutics that address Cytokine Release Syndrome (CRS) caused by viral infections like COVID-19 and others. Over the two pandemic years, more than 540 million people across the world contracted COVID-19 and 6.3 million died from the hyperinflammatory side effects related to this viral infection, which inspired Gb Sciences to create anti-inflammatory drugs designed to treat future viral outbreaks that elicit these dangerous hyperinflammatory responses.
The global anti-inflammatory therapeutics market size was estimated at USD 99.6 billion in 2021, according to Precedence Research, and is expected to hit USD 127.5 billion by 2030, with a registered CAGR of 4.5% from 2022 to 2030. Gb Sciences announced in May 2022 that FHI Clinical would consult and write the draft clinical trial protocol for a first-in-human trial of these proprietary cannabinoid-containing formulations. One key differentiator of Gb Sciences’ CRS therapeutic is the early-intervention and preventative opportunities for patients when they first discover they have been exposed to a virus that causes hyperinflammation. This therapeutic may also be useful for patients who are experiencing CRS as a side effect of certain new cancer therapeutics, such as Bispecific T-cell engaging (BiTE) single-chain antibody constructs and chimeric antigen receptor (CAR) T-cells.
“Our research shows promise for the potential use of cannabinoids within cannabinoid-containing mixtures as a treatment option for hyperinflammation. There is still a need for effective treatments to combat the hyperinflammatory effects of certain viruses. Our cannabis-inspired therapeutics were designed to reset the immune system after hyperinflammation has been triggered, providing relief by targeting our human immune response to a virus, without being tied to a specific variant or the virus itself,” said Andrea Small-Howard, President and Chief Science Officer of Gb Sciences.
Gb Sciences used PhAROS™, its proprietary AI-enabled drug discovery platform, to identify these therapeutic mixtures that were designed to reduce the levels of specific cytokines and pro-inflammatory processes triggered by viruses, while preserving the immune functions and cytokines necessary to fight viral infections. Gb Sciences recently published a white paper on their novel development program titled “Utilizing Proprietary AI/ML Technology, Novel Cannabis-Inspired Mixtures Are Developed as Innovative Anti-Inflammatory Therapeutics”; download it here.
A proof-of-concept study completed by researchers at Michigan State University in 2021 found that Gb Sciences’ proprietary cannabis-inspired minimum essential mixtures (MEM) reduced cytokine release syndrome biomarkers. Gb Sciences’ MEM, containing either two or three cannabinoids each, reduced the levels of inflammatory biomarkers more than the sum of the anti-inflammatory effects of the single ingredients tested separately. The ratios of those cannabinoid molecules within the MEM formulations also greatly influenced their anti-inflammatory potential, the study reported.
To learn more about Gb Sciences, visit www.gbsciences.com.
About Gb Sciences and GbS Global Biopharma
Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary GbS Global Biopharma, Inc. The “plant-inspired” active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-human clinical trial. Gb Sciences’ formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences’ productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects,” “intends,” “plans,” “may,” “could,” “should,” “anticipates,” “likely,” “believes,” and words of similar import may identify forward-looking statements. These statements are not historical facts but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Contact Information:
Alexis Quintal
Press Release Service
by
Newswire.com
Original Source:
Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform
Subscribe if perfectly done #shorts #makeup #beauty #vogue #fashion29
Beauty – Trend Magazine originally published at Beauty – Trend Magazine Beauty – Trend Magazine originally published at Beauty –
Read MoreRadiology Patient Action Network Urges Long-Term Fix for Medicare Payments While Welcoming Limited Support From Congress
“Year-after-year of Medicare funding cuts to independent medical practices must be stopped, and we will continue our congressional advocacy efforts to implement long-term solutions, like inflationary adjustments for in…
Taylor Swift Finally Speaks On Finally Releasing KARMA
Taylor Swift Finally Speaks On Finally Releasing KARMA If there’s one thing Taylor Swift loves it’s dropping Easter eggs and clues, and if there’s one thing Swifties are good at it’s decoding the clues that Taylor drops! Apparently, there’s a secret unreleased album on the way and the detectives have done all the work! But […]
Wilmington Eye Ophthalmic Surgeon Implants First-Ever Glaucoma Device in the Carolinas
This new glaucoma device is the smallest implantable medical device in the world and is the latest advancement in glaucoma care
Robert van der Vaar…
Read More
Ketamine Media Scheduled to Launch North America’s Largest Psilocybin Awareness Network
KNOXVILLE, Tenn. – December 21, 2022 – (Newswire.com)
Ketamine Media announced today that it is in the final stages of launching its digital ecosystem of premium online properties to raise awareness about the clinical use of psilocybin at scale.
Ketamine Media entered the psychedelic medicine space in 2016 to help providers raise awareness about the clinical use of ketamine. With nearly 200 clinics under its marketing management and growing, Ketamine Media is estimated to have at least one-third of the industry’s dedicated ketamine clinics under its umbrella during 2023.
As the benefits of psilocybin become more well-known and legally available, many of Ketamine Media’s existing clinic partners, health centers, and future psilocybin retreats are looking for ways to connect with individuals seeking more information about the possible benefits of psilocybin for PTSD and depression.
Ketamine Media estimates, based on its track record with ketamine and the digital assets already in play, that it should have the country’s largest database of individuals seeking information about the clinical use of psilocybin by the end of 2023.
CEO and co-founder Chris Walden says that Ketamine Media’s objective is simple but more important than ever.
“Over 90% of U.S. adults say that the United States is experiencing a mental health crisis. We have an obligation to make sure that those seeking information about innovative new treatment options get access to accurate information and are introduced to the right medical professionals that can assist them with the proper education and treatment options if they are a good candidate.
“We are living in an exciting time,” says Walden. “A time when medicine like psilocybin, ketamine, and MDMA are within reach and gaining traction quickly with state officials and other countries worldwide.”
“Ketamine Media has been securing premium domains and digital real estate for the last seven years with all forms of psychedelics,” says Walden. The company possesses one of the largest portfolios of premium digital assets in the psychedelic industry.
For questions about Ketamine Media’s services, please contact us.
Contact Information:
Chris Walden
Chief Executive Officer
1-800-975-2291
Press Release Service
by
Newswire.com
Original Source:
Ketamine Media Scheduled to Launch North America’s Largest Psilocybin Awareness Network